Results 271 to 280 of about 427,029 (392)

Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care. [PDF]

Blood Cancer J
Metsemakers SJJPM, Ector GICG, Dinmohamed AG, Hermens RPMG, Blijlevens NMA.   +4 more
europepmc   +1 more source

Chronic Myeloid Leukemia [PDF]

The Journal of Molecular Diagnostics, 2002
openaire   +1 more source

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR^4.5): The phase 2, multicenter N‐Road study

, 2020
Kaichi Nishiwaki, Keiji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Arinobu Tojo, Hisashi Wakita   +13 more
openalex   +1 more source

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

New England Journal of Medicine, 2010
G. Saglio, Dong-Wook Kim, S. Issaragrisil, P. le Coutre, G. Étienne, C. Lobo, R. Pasquini, R. Clark, A. Hochhaus, T. Hughes, N. Gallagher, A. Hoenekopp, M. Dong, A. Haque, R. Larson, H. Kantarjian   +15 more
semanticscholar   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

The Anti-Leukemic Potential of Curcumin in Chronic Myeloid Leukemia: A Systematic Review of In Vitro Studies. [PDF]

Food Sci Nutr
Bahari H, Salim Z, Kardanpour L, Kouchaki H, Shoja F, Rahnama I, Faridzadeh A, Zahedani MR.   +7 more
europepmc   +1 more source

Bone Marrow Fibrosis in Chronic myeloid leukemia (CML) and other Myeloproliferative Disorders Evaluated by Using Special Histochemical Stains for Collagen.

, 2011
Ali Khalil I. Al-Khafaji, Haider Hasan Jaleel Al-Shammari, Salim R. Hamudi Al-Obeidi   +2 more
openalex   +2 more sources

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

Nature Medicine, 2017
Alice Giustacchini, S. Thongjuea, Nikolaos Barkas, P. Woll, B. Povinelli, Christopher A. G. Booth, P. Sopp, Ruggiero Norfo, A. Rodriguez-Meira, N. Ashley, Lauren Jamieson, P. Vyas, K. Anderson, Å. Segerstolpe, H. Qian, U. Olsson‐Strömberg, S. Mustjoki, R. Sandberg, S. Jacobsen, A. Mead   +19 more
semanticscholar   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Supplementary Material for: Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review

figshare admin karger, Gameil A., Ghasoub R., Nasrin Jafari, Shafei L., Benkhadra M., Laws S., H. A. Hamad, Sabet I., Milojkovic D., Fernyhough L.   +10 more
openalex   +1 more source